Reaction Details Report a problem with these data
Target
RAC-beta serine/threonine-protein kinase
Ligand
BDBM50192071
Substrate
n/a
Meas. Tech.
ChEMBL_404551 (CHEMBL910934)
IC50
>1000±n/a nM
Citation
 Kawanishi, N; Sugimoto, T; Shibata, J; Nakamura, K; Masutani, K; Ikuta, M; Hirai, H Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure. Bioorg Med Chem Lett 16:5122-6 (2006) [PubMed]  Article 
Target
Name:
RAC-beta serine/threonine-protein kinase
Synonyms:
AKT2 | AKT2_HUMAN | PKB beta | Protein kinase Akt-2 | Protein kinase B (Akt 2) | Protein kinase B beta (AKT2) | Protein kinase B, beta | RAC-PK-beta | RAC-alpha serine/threonine-protein kinase (AKT2) | RAC-beta serine/threonine-protein kinase | RAC-beta serine/threonine-protein kinase (AKT2) | Serine/threonine-protein kinase AKT | Serine/threonine-protein kinase AKT2 | Serine/threonine-protein kinase Rac alpha/beta
Type:
Enzyme
Mol. Mass.:
55766.64
Organism:
Homo sapiens (Human)
Description:
n/a
Residue:
481
Sequence:
MNEVSVIKEGWLHKRGEYIKTWRPRYFLLKSDGSFIGYKERPEAPDQTLPPLNNFSVAECQLMKTERPRPNTFVIRCLQWTTVIERTFHVDSPDEREEWMRAIQMVANSLKQRAPGEDPMDYKCGSPSDSSTTEEMEVAVSKARAKVTMNDFDYLKLLGKGTFGKVILVREKATGRYYAMKILRKEVIIAKDEVAHTVTESRVLQNTRHPFLTALKYAFQTHDRLCFVMEYANGGELFFHLSRERVFTEERARFYGAEIVSALEYLHSRDVVYRDIKLENLMLDKDGHIKITDFGLCKEGISDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHERLFELILMEEIRFPRTLSPEAKSLLAGLLKKDPKQRLGGGPSDAKEVMEHRFFLSINWQDVVQKKLLPPFKPQVTSEVDTRYFDDEFTAQSITITPPDRYDSLGLLELDQRTHFPQFSYSASIRE
  
Inhibitor
Name:
BDBM50192071
Synonyms:
(13R,15S)-13-methyl-16-oxa-8,9,12,22,24-pentaazahexacyclo[15.6.2.1^{6,9}.1^{12,15}.0^{2,7}.0^{21,25}]heptacosa-1(24),2,4,6(27),7,17(25),18,20,22-nonaene-23,27-diol | CHEMBL215803
Type:
Small organic molecule
Emp. Form.:
C22H21N5O3
Mol. Mass.:
403.4338
SMILES:
C[C@@H]1C[C@H]2CN1CCn1[nH]c3c(cccc3c1=O)-c1nc3c(O2)cccc3[nH]c1=O
Structure:
Search PDB for entries with ligand similarity: